Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Rgenta Therapeutics Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct art units, suggesting that the company's research and development efforts cover different specialized niches within the biological sciences. Because the workload is divided between 2 distinct art units, the prosecution strategy must be flexible enough to address the specific technical guidelines and examination practices of each group.
The portfolio is being handled by 2 distinct examiners, with each of the 2 pending office actions assigned to a different individual. RAHMANI, NILOOFAR is the busiest examiner, responsible for 1 pending office action. This distribution means that no single examiner's decisions will determine the overall success of the company's current patent efforts. To effectively manage its 2 pending office actions in Biotechnology & Pharmaceuticals, the company must provide precise technical arguments that meet the requirements of the 2 distinct examiners. This decentralized approach requires careful coordination to ensure that the prosecution of each application remains consistent with the company's broader intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18710312 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | MCDOWELL, BRIAN E | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711986 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RAHMANI, NILOOFAR | 1691 | §112 | Non-Final OA | — | Pending | May 21, 2024 |
| 18710312 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | — | Pending | May 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRgenta Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Niloofar Rahmani has the most, with 1 of Rgenta Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
